T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Northern Oil and Gas
NOG
$2.54B
| $953K | ﹤0.01% |
14,070
-1,290
| -8% | -$98.6K |
|
1752
Kennametal
KMT
$2.35B
| $949K | ﹤0.01% |
27,800
| – | – |
|
1753
WaFd
WAFD
$2.81B
| $946K | ﹤0.01% |
40,510
-3,100
| -7% | -$69.5K |
|
1754
Amkor Technology
AMKR
$14.4B
| $942K | ﹤0.01% |
157,453
-19,200
| -11% | -$138K |
|
1755
Saic
SAIC
$5.3B
| $942K | ﹤0.01% |
17,828
| – | – |
|
|
OPWR
1756
DELISTED
OPOWER INC COM STK (DE)
OPWR
| $942K | ﹤0.01% |
81,800
| – | – |
|
|
WNR
1757
DELISTED
Western Refining Inc
WNR
| $942K | ﹤0.01% |
21,600
| – | – |
|
|
BMR
1758
DELISTED
BIOMED REALTY TRUST INC
BMR
| $936K | ﹤0.01% |
48,400
| – | – |
|
|
DFT
1759
DELISTED
DuPont Fabros Technology Inc.
DFT
| $931K | ﹤0.01% |
31,600
+500
| +2% | +$15.9K |
|
1760
Avista
AVA
$3.25B
| $928K | ﹤0.01% |
30,290
| – | – |
|
1761
Darling Ingredients
DAR
$10.2B
| $927K | ﹤0.01% |
63,200
| – | – |
|
|
ADVS
1762
DELISTED
Advent Software Inc
ADVS
| $924K | ﹤0.01% |
20,900
-205,100
| -91% | -$8.97M |
|
1763
Chegg
CHGG
$85.6M
| $922K | ﹤0.01% |
+117,591
| New | +$931K |
|
|
UMPQ
1764
DELISTED
Umpqua Holdings Corp
UMPQ
| $922K | ﹤0.01% |
51,265
+9,300
| +22% | +$164K |
|
1765
Associated Banc-Corp
ASB
$6.09B
| $917K | ﹤0.01% |
45,242
| – | – |
|
1766
Delek US
DK
$4.14B
| $917K | ﹤0.01% |
24,900
| – | – |
|
1767
Insperity
NSP
$1.97B
| $914K | ﹤0.01% |
35,900
+11,600
| +48% | +$303K |
|
1768
Brookfield
BN
$109B
| $912K | ﹤0.01% |
+74,322
| New | +$946K |
|
|
CHL
1769
DELISTED
China Mobile Limited
CHL
| $906K | ﹤0.01% |
14,131
+1,515
| +12% | +$103K |
|
1770
iShares MSCI Japan ETF
EWJ
$23.2B
| $904K | ﹤0.01% |
17,650
-20,850
| -54% | -$1.09M |
|
1771
Invesco Mortgage Capital
IVR
$812M
| $899K | ﹤0.01% |
6,280
| – | – |
|
1772
Silgan Holdings
SLGN
$4.43B
| $898K | ﹤0.01% |
34,040
| – | – |
|
|
UNIT
1773
Uniti Group
UNIT
$2.36B
| $897K | ﹤0.01% |
+36,304
| New | +$980K |
|
1774
CubeSmart
CUBE
$9.4B
| $896K | ﹤0.01% |
38,700
| – | – |
|
|
STR
1775
DELISTED
QUESTAR CORP
STR
| $893K | ﹤0.01% |
42,700
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.